ArticleVaccine2010
Vaccines delivered by integration-deficient lentiviral vectors targeting dendritic cells induces strong antigen-specific immunity.
Article in Vaccine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 44 citations in OpenAlex.
- Article
- Lentiviral Vectors as a Vaccine Platform against Infectious Diseases.Pharmaceutics · 2023Review
- Early protective effect of a ("pan") coronavirus vaccine (PanCoVac) in Roborovski dwarf hamsters after single-low dose intranasal administration.Frontiers in immunology · 2023Article
- Review
- Review
- Skeletal Muscle Is an Antigen Reservoir in Integrase-Defective Lentiviral Vector-Induced Long-Term Immunity.Molecular therapy. Methods & clinical development · 2020Article
- IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells.Communications biology · 2018Article
- Recent Advances in Lentiviral Vaccines for HIV-1 Infection.Frontiers in immunology · 2016Review
- Generation of a stable packaging cell line producing high-titer PPT-deleted integration-deficient lentiviral vectors.Molecular therapy. Methods & clinical development · 2015Article
- Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines.Journal of immunology research · 2015Review
- Integration-deficient lentiviral vectors expressing codon-optimized R338L human FIX restore normal hemostasis in Hemophilia B mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Induction of antigen-specific immune responses by dendritic cells transduced with a recombinant lentiviral vector encoding MAGE-A3 gene.Journal of cancer research and clinical oncology · 2014Article
- Design and Potential of Non-Integrating Lentiviral Vectors.Biomedicines · 2014Review
- Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.New journal of science · 2014Article
- Perspectives on reprograming cancer-associated dendritic cells for anti-tumor therapies.Frontiers in oncology · 2014Review
- Optimization of mucosal responses after intramuscular immunization with integrase defective lentiviral vector.PloS one · 2014Article
- Lentiviral vectors containing mouse Csf1r control elements direct macrophage-restricted expression in multiple species of birds and mammals.Molecular therapy. Methods & clinical development · 2014Article
- Gene therapy on the move.EMBO molecular medicine · 2013Review
- Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?Oncoimmunology · 2013Review
- Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART.Gene therapy · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
We report a study of an integration-deficient lentiviral vector (IDLV) enveloped with a Sindbis virus glycoprotein mutant (SVGmu) capable of selectively binding to dendritic cells (DCs) for its potential as a vaccine carrier. The in vitro assays showed that the D64V point mutation in the catalytic domain of HIV-1 integrase efficiently inhibited the integration of the transgene upon vector transduction, while the targeting specificity of the vector to preferentially transduce and mediate durable expression in DCs was maintained. Substantial immune responses in C57BL/6 mice and complete protection against a challenge with the C57BL/6 thymoma EG.7 tumor expressing a delivered ovalbumin (OVA) antigen in mice have been achieved through the direct injection of the DC-directed IDLV encoding OVA. Thus, this DC-directed IDLV system represents a promising and efficient vector platform with remarkably improved safety for the future development of DC-based immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.